Mobilizing the Immune SystemA clinical-stage biopharmaceutical company leveraging from its multiple drug development platforms to treat patients with inflammatory diseases, viral infections, and cancer.
Fighting Inflammatory DiseasesAbivax’s lead candidate ABX464, a potent anti-inflammatory agent, is being tested in a Phase 2b clinical trial for its potential to bring clinical benefit to patients with ulcerative colitis, and potentially other inflammatory indications.
Developing a Functional Cure for HIVABX464 is a Phase 2 candidate designed to functionally cure HIV by reducing the viral reservoir and is the first ever drug candidate to demonstrate this reduction in patients.
Tackling CancerA small molecule agonist of invariant Natural Killer T-Cells (iNKT) is currently being tested in a Phase 1/2 clinical trial for treatment of hepatocellular carcinoma (HCC).
Abivax is developing therapies that stimulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, HIV, and liver cancer.
Its lead clinical candidate, ABX464, has demonstrated the potential to treat inflammatory diseases and to reduce the viral reservoir in HIV.
Abivax recently presented impressive results from its ABX464 maintenance study in ulcerative colitis at the United European Gastroenterology Conference, UEG Week 2019, in Barcelona, Spain on October 21, 2019. This data showed that impressive efficacy initially reported at 8 weeks after completion of the induction study is durable or improving at 12 months with ABX464. You can see documentation from these presentations here:
With four products in clinical testing, a trial in Crohn’s disease to start and three products in research and preclinical development, Abivax’s pipeline is strong and diversified, addressing many unmet needs.
News & Events
Abivax SA has been listed on the Paris stock exchange since June 26, 2015.